MIMEDX Provides Insights on Final Rule for Medicare Physician Fee Schedule for Calendar Year 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Source: Newsfilter
CMS Reimbursement Reform: MiMedx Group, Inc. has commented on the Centers for Medicare and Medicaid Services' release of the CY 2026 Physician Fee Schedule, which aims to address fraud and improve the Medicare reimbursement system for skin substitutes.
Company's Preparedness: CEO Joseph H. Capper expressed confidence in MiMedx's ability to leverage its competitive advantages in response to the new reimbursement environment, despite some preferred recommendations not being included in the final rule.
Focus on Patient Access: The company emphasizes its commitment to ensuring that patients continue to have access to its proven technology during the transition to the new reimbursement system.
Forward-Looking Statements: The press release includes forward-looking statements regarding the impact of reimbursement changes, cautioning investors about the inherent risks and uncertainties associated with such predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDXG
Wall Street analysts forecast MDXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXG is 11.75 USD with a low forecast of 10.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.140
Low
10.00
Averages
11.75
High
13.00
Current: 5.140
Low
10.00
Averages
11.75
High
13.00
About MDXG
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MDXG Stock Fluctuates: 52-Week Low at $5.79
- Stock Fluctuation: MDXG's 52-week low is $5.79 per share, with a high of $9.71, and the last trade at $6.90 indicates significant price volatility, reflecting market uncertainty regarding the company's future performance.
- Market Trends: The current price of $6.90 is close to the 52-week low, which may impact investor confidence, particularly as the company faces competitive pressures and industry challenges, necessitating close monitoring of its subsequent performance.
- Technical Indicators: MDXG's stock has fallen below its 200-day moving average, suggesting potential further downside pressure in the short term, prompting investors to carefully assess holding risks.
- Investor Focus: As the stock approaches its 52-week low, investors may reconsider their investment strategies, especially amid increasing market volatility, highlighting the need to closely watch the company's future financial performance and market dynamics.
Continue Reading
MiMedx (MDXG) Enters Exclusive Distribution Agreement for RegenKit-Wound Gel
- Exclusive Agreement: MiMedx has signed an exclusive agreement with Regen Lab USA to distribute the RegenKit-Wound Gel in the U.S., adding a differentiated option to its Advanced Wound Care portfolio with this autologous platelet-rich plasma and autologous thrombin serum solution.
- Clinical Validation: The RegenKit-Wound Gel has been validated by multiple published studies for its effectiveness in treating chronic wounds, and since its FDA approval in 2022, it has been nationally covered by CMS and LCD, enhancing its market competitiveness.
- Market Expansion Strategy: By introducing RegenKit, MiMedx continues to broaden its wound care product offerings, which is expected to provide patients and healthcare professionals with a wider array of proven solutions, thereby strengthening the company's position in the rapidly growing wound care market.
- Policy Advantage: The clarity on Local Coverage Determination (LCD) implementation set for January 1, 2026, positions MiMedx in an incredibly strong competitive stance as it prepares to enter the new year, further solidifying its market leadership.
Continue Reading